Table 4.

Design and main results of the fourteen studies enrolled in the review

First author, year	Study design	Main results
Zhang, 2020	Retrospective study	Patients with high FAR-SIRI scores had poorer OS.
Topkan. 2020	Retrospective study	The lower SIRI had significantly superior PFS and OS.
Yeşil, 2020	Retrospective study	Low SIRI value was associated with increased OS, while was not associated with increased PFS.
Li, 2021	Cross-sectional study	Combined detection of CA19-9, NLR and SIRI are of higher value in the early diagnosis of pancreatic cancer.
Wang, 2021	Retrospective study	High SIRI was significantly related to poorer tumor response. Low SIRI group had longer PFS and OS.
Cai, 2022	Retrospective study	Patients with a lower NSAP (established based on SIRI) had significantly associated with better. DFS
Mao, 2022	Retrospective study	SIRI was an independent prognostic factor for 1-year RFS in patients after curative resection.
Zheng, 2022	Retrospective study	Higher SIRI was associated with poorer DFS.
Puhr, 2023	Retrospective study	Higher SIRI scores was associated with shorter OS.
Yazici, 2023	Retrospective study	The higher SIRI was associated with male gender, lower serum albumin level, and Clavien-Dindo Grade III and higher complications.
Cai, 2023	Retrospective study	High preoperative C-SIRI was significantly correlated with poorer OS.
Guo, 2023	Retrospective study	Higher SIRI was a risk factor for early recurrence.
Cai, 2023	Retrospective study	Patients with lower SIRI values had significantly better OS.
Liu, 2023	Retrospective study	High SIRI was not associated with OS and PFS.

DFS, disease-free survival; OS, overall survival; PFS, progression-free survival; SIRI, systemic inflammation response index